Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(88)
•••
Comment by SABBOBCATon Feb 11, 2020 9:51am
60 Views
Post# 30673184

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Material fact

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Material fact If the stick price doest move I don't see how Luc can make it unscathed. A compitent board would need to take action with lackluster sales and an SP in the gutter.... That is if we have a compitent board
SABBOBCAT wrote: Hahaha I'd help hold the door while you do it!
palinc2000 wrote: We are all on the same bus and unfortunately the driver has a class C driver"s license instead of a Class A  and is still using a traditional road map rather than a sophisticated Navigation system

On the other hand the bus itself is still rooad worthy but is in dire need of a driver holding a Class A drivers license

Since you are sitting in the front of the bus why dont you push the driver out at the next pit stop and get a driver who will not only drive the bus in the right direction but will also be equipped with a microphone to keep the passengers informed on the points of interest on the way to destination




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities